A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain

Trial Profile

A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Rexlemestrocel-L (Primary) ; Hyaluronic acid
  • Indications Back pain; Intervertebral disc degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors Mesoblast
  • Most Recent Events

    • 19 Apr 2018 Planned End Date changed from 1 Oct 2020 to 1 Mar 2021.
    • 19 Apr 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Mar 2020.
    • 28 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top